Four corporate executives in Navidea Biopharmaceuticals (
) made insider buys into the company on Friday. These buys mark
the first insider transactions for Navidea in 2013. Chief
Business Officer and Executive Vice President Thomas Tulip bought
17,500 shares for $2.82 costing him $49,350. Tulip now holds on
to 49,350 shares. Senior Vice President, William Regan, added
5,000 shares at $2.71 to his stake. This transaction cost Regan
$13,550; he now owns 5,000 shares of the company. Director
Brendan Ford also added 5,000 shares, costing him $13,550. Ford
now holds 119,250 shares of Navidea. Lastly, CEO and President
Mark Pykett added 1,850 shares at $2.70 costing him a total of
Thomas Tulip has been with Navidea since June 2010. He is also on
the Board of Directors at the Council on Radionuclides and
Radiopharmaceuticals (ORAR). Tulip helped develop and
commercialize the first nuclear cardiology franchise.
Brendan Ford has been a partner with Navidea since 2010. He is a
corporate partner with Talisman Capital Partners, a private
investment partnership that focuses on middle market companies.
William Regan is the Senior Vice President of Global Regulatory
Strategy for Navidea. Regan is just starting with the company.
This insider buy marks the first one for Regan.
Mark Pykett has been the CEO and President of Navidea since April
2011. Pykett has worked in the pharmaceutical industry for over
15 years. He holds a degree in veterinary medicine and a Ph.D. in
molecular biology from the University of Pennsylvania.
Navidea Biopharmaceuticals is a biopharmaceutical company that
focuses on developing radiopharmaceutical imaging agents that
help identify the presence and status of disease and enable
better diagnostic accuracy. Navidea is based out of Dublin, Ohio,
and has a market cap of $286.73 million.
Revenues for 2012 were $79,000 compared to $598,000 for 2011.
Operating expenses for 2012 were $28.1 million compared to $24.7
million for 2011. Navidea reports that revenues were down in 2012
due to the reimbursement of Lymphoseek commercialization
activities. In February 2013 the company completed an
underwritten public offering of 1.5 million shares of common
"During 2012, we continued to make important progress positioning
Navidea as a leader in the area of precision diagnostics," said
Dr. Mark Pykett, Navidea's president and CEO. "We are looking
forward to an even more exciting 2013."
There are currently no Gurus followed by GuruFocus that hold
shares in Navidea Biopharmaceuticals.
With its shares up 3.37%, Navidea trades at $2.76.
For more information on insider trades within NAVB look at the
Insider Trade History page
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to